Direct antiviral agents targeting enteroviruses remain unlicensed for severe cases, as several candidates have failed clinical development due to limited efficacy or side effects.
This review highlights the progress and ongoing challenges in developing direct antiviral agents against enteroviruses, emphasizing the need to address current knowledge gaps.
Absolute Event Rate: 0% vs 0%
Enteroviruses represent important human pathogens, posing a substantial disease burden, particularly in children under 5 years of age. Enteroviruses are the primary causative agents of hand-foot-and-mouth disease (HFMD) and are strongly associated with acute flaccid myelitis (AFM), with severe cases potentially resulting in significant neurological complications. Inactivated vaccines against EV-A71 based on the C4 genotype are currently available. However, there are no licensed direct antiviral agents for severe cases. By focusing on viral proteins and host factors, researchers have made great strides in the creation of antiviral medications that target enteroviruses. However, several viral candidates failed to progress in clinical development due to limited efficacy or side effects. This review discusses key findings in enterovirus antiviral research, analyzes the advantages and limitations of each drug target, and highlights knowledge gaps that need to be addressed to advance further development in this field.
Lu et al. (Sat,) reported a other. Direct antiviral agents targeting enteroviruses remain unlicensed for severe cases, as several candidates have failed clinical development due to limited efficacy or side effects.